在多发性骨髓瘤中使用MCL1抑制剂
Emily Nelson1, Sandesh P Telang2, Tulin Budak-Alpdogan3
1Department of Chemistry and Biochemistry, Rowan University, Glassboro, NJ 08028, USA.
Biochemical pharmacology
|November 9, 2025
概括
骨髓细胞白血病1 (MCL1) 蛋白质是克服多发性骨髓瘤 (MM) 耐药性的关键标. 本综述详细介绍了MM临床试验中MCL1抑制剂的历史和进展情况,并指出了诸如心脏毒性等挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨髓细胞白血病1 (MCL1) 是一种在多发性骨髓瘤 (MM) 等癌症中过度表达的抗亡蛋白,有助于药物耐药性.
- 抑制MCL1是一种有希望的策略,可以克服MM的治疗耐药性.
- 自1993年发现MCL1抑制剂以来,MCL1抑制剂的开发已经取得了显著的进展.
研究的目的:
- 审查多发性骨髓瘤的MCL1抑制策略的历史发展和当前进展.
- 突出分子方法,临床前小分子抑制剂和R/R MM中MCL1抑制剂的临床试验.
- 讨论与MCL1抑制剂相关的挑战,包括心脏毒性等不良影响.
主要方法:
- 在多发性髓瘤中对MCL1抑制的文献综述.
- 对历史和当前临床前小分子抑制剂的分析,针对MCL1.
- 对复发性/耐药性MM患者的MCL1抑制剂临床试验数据的检查.
主要成果:
- 第一个选择性MCL1抑制剂 (A-1210477) 在2008年开发出来.
- 在R/RMM患者的临床试验中,已经评估了6种新的MCL1抑制剂.
- 心脏毒性和其他不良影响是临床应用的重大障碍.
结论:
- 抑制MCL1是克服MM药物耐药性的关键治疗策略.
- 尽管取得了进展,但不良影响,特别是心脏毒性,仍然是MCL1抑制剂的挑战.
- 对新的MCL1抑制剂和减轻副作用的策略的持续研究对于有效的MM治疗至关重要.
相关概念视频
02:23Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K